Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: BIOLOGICAL: ramucirumab (IMC-1121B)|DRUG: docetaxel|OTHER: Placebo
Sponsor: Eli Lilly and Company